AU2019394956B2 - Methods of treating neurological and psychiatric disorders - Google Patents

Methods of treating neurological and psychiatric disorders Download PDF

Info

Publication number
AU2019394956B2
AU2019394956B2 AU2019394956A AU2019394956A AU2019394956B2 AU 2019394956 B2 AU2019394956 B2 AU 2019394956B2 AU 2019394956 A AU2019394956 A AU 2019394956A AU 2019394956 A AU2019394956 A AU 2019394956A AU 2019394956 B2 AU2019394956 B2 AU 2019394956B2
Authority
AU
Australia
Prior art keywords
compound
disorder
patient
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019394956A
Other languages
English (en)
Other versions
AU2019394956A1 (en
Inventor
Seth Cabot Hopkins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma America Inc
Original Assignee
Sumitomo Pharma America Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharma America Inc filed Critical Sumitomo Pharma America Inc
Publication of AU2019394956A1 publication Critical patent/AU2019394956A1/en
Application granted granted Critical
Publication of AU2019394956B2 publication Critical patent/AU2019394956B2/en
Priority to AU2025213591A priority Critical patent/AU2025213591A1/en
Assigned to SUMITOMO PHARMA AMERICA, INC. reassignment SUMITOMO PHARMA AMERICA, INC. Request for Assignment Assignors: SUNOVION PHARMACEUTICALS INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2019394956A 2018-12-06 2019-12-05 Methods of treating neurological and psychiatric disorders Active AU2019394956B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025213591A AU2025213591A1 (en) 2018-12-06 2025-08-06 Methods of treating neurological and psychiatric disorders

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862776247P 2018-12-06 2018-12-06
US62/776,247 2018-12-06
US201962829796P 2019-04-05 2019-04-05
US62/829,796 2019-04-05
PCT/US2019/064646 WO2020118032A1 (en) 2018-12-06 2019-12-05 Methods of treating neurological and psychiatric disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025213591A Division AU2025213591A1 (en) 2018-12-06 2025-08-06 Methods of treating neurological and psychiatric disorders

Publications (2)

Publication Number Publication Date
AU2019394956A1 AU2019394956A1 (en) 2021-06-17
AU2019394956B2 true AU2019394956B2 (en) 2025-05-08

Family

ID=69024675

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019394956A Active AU2019394956B2 (en) 2018-12-06 2019-12-05 Methods of treating neurological and psychiatric disorders
AU2025213591A Pending AU2025213591A1 (en) 2018-12-06 2025-08-06 Methods of treating neurological and psychiatric disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025213591A Pending AU2025213591A1 (en) 2018-12-06 2025-08-06 Methods of treating neurological and psychiatric disorders

Country Status (9)

Country Link
US (3) US20200179336A1 (enExample)
EP (1) EP3890726A1 (enExample)
JP (2) JP2022511509A (enExample)
KR (1) KR20210100667A (enExample)
CN (2) CN118576586A (enExample)
AU (2) AU2019394956B2 (enExample)
CA (1) CA3122261A1 (enExample)
MX (1) MX2021006553A (enExample)
WO (1) WO2020118032A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104193761B (zh) 2009-12-04 2017-10-17 桑诺维恩药品公司 多环化合物及其使用方法
BR112019001407A2 (pt) 2016-07-29 2019-07-09 Sunovion Pharmaceuticals Inc. compostos e composições e usos dos mesmos
EP3582815A1 (en) 2017-02-16 2019-12-25 Sunovion Pharmaceuticals Inc. Methods of treating schizophrenia
MX2020000523A (es) 2017-08-02 2020-08-20 Sunovion Pharmaceuticals Inc Compuestos de isocromano y usos de los mismos.
SG11202007823PA (en) 2018-02-16 2020-09-29 Sunovion Pharmaceuticals Inc Salts, crystal forms, and production methods thereof
KR20230003503A (ko) 2020-04-14 2023-01-06 선오비온 파마슈티컬스 인코포레이티드 신경학적 및 정신의학적 장애의 치료를 위한 (S)-(4,5-디히드로-7H-티에노[2,3-c]피란-7-일)-N-메틸메탄아민
US20220165391A1 (en) * 2020-11-25 2022-05-26 Kyndryl, Inc. Multi-stage treatment recommendations
KR20240110935A (ko) * 2021-09-23 2024-07-16 스미토모 파마 아메리카, 인크. 대사 장애를 치료하는 방법
CA3260160A1 (en) 2022-08-30 2024-03-07 Sumitomo Pharma America, Inc. ULOTARONT FOR THE ADJUVANT TREATMENT OF MAJOR DEPRESSIVE DISORDER
AU2023358704A1 (en) 2022-10-13 2025-05-29 Sumitomo Pharma America, Inc. Methods of reducing physical dependence to neuropsychiatric treatments
WO2024092070A1 (en) * 2022-10-28 2024-05-02 Sumitomo Pharma America, Inc. Ulotaront for treating anxiety and associated conditions
CN120187422A (zh) 2022-11-15 2025-06-20 住友制药美国公司 使用ulotaront转换神经精神病学药物的方法
CN115754079B (zh) * 2022-11-28 2025-04-04 合肥和合医疗科技有限公司 一种同时检测7种精神药物及其代谢产物含量的方法
CN117594119B (zh) * 2024-01-17 2024-05-10 北京大学第六医院 用于预测帕罗西汀或其药用盐对抑郁或焦虑症患者疗效的装置
WO2025252814A1 (en) 2024-06-04 2025-12-11 Duc Duy Vo Methods for treating trace amine-associated receptor 1 (taar1)-associated diseases or disorders comprising administration of novel taar1 agonists or pharmaceutical compositions thereof
WO2026015878A1 (en) * 2024-07-12 2026-01-15 Mindx Therapeutics, Inc. A new combination therapy for treatment-resistant depression in patients with co-morbid metabolic syndrome

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011069063A2 (en) * 2009-12-04 2011-06-09 Sunovion Pharmaceuticals, Inc. Multicyclic compounds and methods of use thereof
WO2018151861A1 (en) * 2017-02-16 2018-08-23 Sunovion Pharamaceuticials Inc. Methods of treating schizophrenia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202007823PA (en) 2018-02-16 2020-09-29 Sunovion Pharmaceuticals Inc Salts, crystal forms, and production methods thereof
WO2019161236A1 (en) * 2018-02-16 2019-08-22 Sunovion Pharmaceuticals Inc. Methods of treating social function disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011069063A2 (en) * 2009-12-04 2011-06-09 Sunovion Pharmaceuticals, Inc. Multicyclic compounds and methods of use thereof
WO2018151861A1 (en) * 2017-02-16 2018-08-23 Sunovion Pharamaceuticials Inc. Methods of treating schizophrenia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KOBLAN KENNETH ET AL: "A Phase 1 Open Label Safety and Tolerability Study of SEP-363856, a Novel NON-D2 Mechanism of Action Molecule, in Patients With Schizophrenia", NEUROPSYCHOPHARMACOLOGY, vol. 41, no. Suppl. 1, December 2016 *

Also Published As

Publication number Publication date
CA3122261A1 (en) 2020-06-11
KR20210100667A (ko) 2021-08-17
MX2021006553A (es) 2021-09-08
CN118576586A (zh) 2024-09-03
US20240350453A1 (en) 2024-10-24
AU2025213591A1 (en) 2025-08-21
JP2025024102A (ja) 2025-02-19
JP2022511509A (ja) 2022-01-31
US20200179336A1 (en) 2020-06-11
CN113271936A (zh) 2021-08-17
US20250312308A1 (en) 2025-10-09
AU2019394956A1 (en) 2021-06-17
WO2020118032A1 (en) 2020-06-11
EP3890726A1 (en) 2021-10-13

Similar Documents

Publication Publication Date Title
US20250312308A1 (en) Methods of treating neurological and psychiatric disorders
EP4135690B1 (en) (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating, preventing and/or managing a neurological and/or psychiatric disorder
AU2018201060B2 (en) 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto
RU2757221C2 (ru) Фармацевтические композиции, содержащие антипсихотическое лекарственное средство и ингибитор vmat2, и их применение
CN114340670B (zh) T-型钙通道调节剂的制剂及其使用方法
US12161758B2 (en) Modified release formulations and uses thereof
UA122780C2 (uk) Композиції, що містять 2-((1-(2-(4-фторфеніл)-2-оксоетил)піперидин-4-іл)метил)ізоіндолін-1-он, для лікування шизофренії
CN115776894A (zh) T型钙通道调节剂的使用方法
MX2008000250A (es) Combinaciones de eszopiclona y trans-4-(3,4-diclorofenil)-1,2,3,4- tetrahidro-n-metil-1-naftalenamina o trans 4-(3,4-diclorofenil)-1, 2,3,4-tetrahidro-1-naftalenamina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y
HK40057761A (en) Methods of treating neurological and psychiatric disorders
WO2021188148A1 (en) Crystalline forms of squalamine
JP2023503271A (ja) （２ｒ，６ｒ）－ヒドロキシノルケタミンの塩、それらの結晶形、およびその製造方法
JP2022087834A (ja) 放出調節製剤およびその使用
HK40064212A (en) Modified release formulations and uses thereof
US20160367503A1 (en) Combination Medication for Neuro-Degenerative Diseases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: SUMITOMO PHARMA AMERICA, INC.

Free format text: FORMER OWNER(S): SUNOVION PHARMACEUTICALS INC.